[Translation] An open, multicenter, Phase Ia clinical study to evaluate the safety, efficacy, and pharmacokinetic characteristics of LF0376 tablets as a single agent in the treatment of patients with advanced solid tumors and lymphomas such as colorectal cancer, pancreatic cancer, and liver cancer
主要目的:
1、评价LF0376片的安全性和耐受性;
2、确定LF0376片的最大耐受剂量(MTD)和后续研究的合适推荐剂量(RD)。
次要目的:
1、评价LF0376片的药代动力学(PK)特征;
2、初步评价LF0376片治疗结直肠癌、胰腺癌、肝癌等晚期实体瘤和淋巴瘤患者的有效性
[Translation] Main objectives:
1. Evaluate the safety and tolerability of LF0376 tablets;
2. Determine the maximum tolerated dose (MTD) of LF0376 tablets and the appropriate recommended dose (RD) for subsequent studies.
Secondary objectives:
1. Evaluate the pharmacokinetic (PK) characteristics of LF0376 tablets;
2. Preliminary evaluation of the effectiveness of LF0376 tablets in the treatment of patients with advanced solid tumors and lymphomas such as colorectal cancer, pancreatic cancer, and liver cancer